Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Olson

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
Cancer Discovery|October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsJill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Cancer Cell|February 25, 2024
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancerXinyuan Tong, Ayushi S Patel, Eejung Kim, et al.
Science (New York, N.Y.)|June 6, 2024
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancersJeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker, et al.
The New England Journal of Medicine|June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in CancerMark M Awad, Shengwu Liu, Igor I Rybkin, et al.
Cancer Discovery|July 8, 2024
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Megan T Hoffman, Laleh Abbassi, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
Cancer Discovery|October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsJill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Cancer Cell|February 25, 2024
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancerXinyuan Tong, Ayushi S Patel, Eejung Kim, et al.
Science (New York, N.Y.)|June 6, 2024
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancersJeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker, et al.
The New England Journal of Medicine|June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in CancerMark M Awad, Shengwu Liu, Igor I Rybkin, et al.
Cancer Discovery|July 8, 2024
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic CancerJulien Dilly, Megan T Hoffman, Laleh Abbassi, et al.
Pageof 7